New products are popular, pension finance plays a characteristic card

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

China’s Liquor Giant Kweichow Moutai Achieved 20% of Revenue Increase in February

On March 7, China’s biggest liquor distiller Kweichow Moutai released that the company achieved up to 20% of year-on-year revenue increase from January to February 2022.

China's 2015-2020 Semiconductor Leap, in 2 Charts

Seeing a lot of progress, the country, however, is yet to avoid the guns-and-butter situation, serving the global industry primarily within the capital and labor-driven realms.